MNKD Trend continuation, possible bullish outlook as long as price can stay above channel.
MNKD (with partner Sanofi) is about to market and distribute FDA approved Afrezza, a inhaled insulin that can make insulin syringes a thing of the past. With diabetes a global condition that effects 371 million people worldwide and is expected to affect 552 million by 2030, MNKD is the only FDA approved product of this kind.
